Saint-Gobain adds high purity option to Sani-Tech line
Ultra-HP combines reinforced outer jacket with fully bonded FEP liner
Ultra-HP combines a tough outer jacket and hose comprising multiple layers of Sani-Tech Ultra platinum-cured silicone and 316L stainless steel helical wire reinforcement with a PharmaFluor FEP liner. The liner's smooth inner bore surface provides both optimal flow and ease of cleaning and sanitisation.
The PharmaFluor FEP liner is said to minimise bonding of biological materials and maintains fluid purity due to low TOCs, extractables and leachables. The liner is fully bonded to the silicone hose using a patented bonding technology, which helps ensure a high purity fluid path.
The company says the hose's overall light weight, low force to bend and exceptional flexibility make it suitable for a variety of applications, including bioprocessing, load cells, product transfer and steam-in-place/clean-in-place (SIP/CIP).
Sani-Tech Ultra-HP hose is made from USP Class VI compliant materials and certified to meet USP <88>, USP <87>, EP 3.1.9, ISO 10993, FDA 21 CFR 177.2600 and FDA 21 CFR 177.1550 requirements.
You may also like
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months